[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R: Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol; 2010 Feb 20;28(6):967-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
  • PURPOSE To investigate the management of bone health in women with early breast cancer (EBC) who were scheduled to receive anastrozole.
  • Lumbar spine and total hip bone mineral density (BMD) were assessed at baseline, 12 months, and 24 months.
  • Results At 24 months, in the M group, treatment with A + R resulted in a significant increase in lumbar spine and total hip BMD compared with A + P treatment (2.2% v -1.8%; treatment ratio, 1.04; P < .0001; and 1.8% v -1.1%; treatment ratio, 1.03; P < .0001, respectively).
  • In the H stratum, lumbar spine and total hip BMD increased significantly (3.0%; P = .0006; and 2.0%; P = .0104, respectively).
  • Patients in the L stratum showed a significant decrease in lumbar spine BMD (-2.1%; P = .0109) and a numerical decrease in total hip BMD (-0.4%; P = .5988).
  • [MeSH-major] Aromatase Inhibitors / adverse effects. Bone Density Conservation Agents / therapeutic use. Breast Neoplasms / drug therapy. Etidronic Acid / analogs & derivatives. Fractures, Bone / prevention & control. Nitriles / adverse effects. Osteoporosis, Postmenopausal / prevention & control. Triazoles / adverse effects
  • [MeSH-minor] Aged. Bone Density / drug effects. Double-Blind Method. Female. Hormone Replacement Therapy. Humans. Middle Aged. Neoplasm Staging. Postmenopause. Prognosis. Risedronate Sodium. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Fractures.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • Hazardous Substances Data Bank. 1-HYDROXY-1,1-DIPHOSPHONOETHANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065185.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Bone Density Conservation Agents; 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole; M2F465ROXU / Etidronic Acid; OFG5EXG60L / Risedronate Sodium
  •  go-up   go-down


2. Fukuda Y, Fujio N, Takatori H, Tsukazaki T, Terakura M, Mayumi K, Koyama I, Tsukazaki Y, Osugi H: [Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases]. Gan To Kagaku Ryoho; 2004 Jan;31(1):107-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases].
  • We report a case in which low-dose FP (5-fluorouracil/cisplatin, 5-FU/CDDP) therapy was remarkably effective for stage IVB advanced hepatocellular carcinoma (HCC) with lung and bone metastases.
  • The patient complained of lumbago and hip pain in July 2001 and was admitted for dysbasia in September 2001.
  • Chest computed tomography (CT) showed multiple bilateral lung metastases and abdominal CT showed a tumor 12 x 11 x 10 cm in diameter in the right, iliac bone.
  • The CT findings revealed that a complete response (CR) was obtained for lung metastases and a partial response (PR) was obtained for bone metastases after completion of course 2, and maintained thereafter.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / secondary
  • [MeSH-minor] Aged. Aged, 80 and over. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Neoplasm Staging. Quality of Life. Remission Induction

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14750333.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


3. Tsai YC, Wu CT, Hong RL: Response of refractory osteosarcoma to thalidomide and celecoxib. Lancet Oncol; 2005 Dec;6(12):997-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Immunosuppressive Agents / therapeutic use. Osteosarcoma / drug therapy. Osteosarcoma / pathology. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Celecoxib. Drug Resistance, Neoplasm. Drug Therapy, Combination. Hip / pathology. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321769.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Immunosuppressive Agents; 0 / Pyrazoles; 0 / Sulfonamides; 4Z8R6ORS6L / Thalidomide; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


Advertisement
4. Schwartz AJ, Kiatisevi P, Eilber FC, Eilber FR, Eckardt JJ: The Friedman-Eilber resection arthroplasty of the pelvis. Clin Orthop Relat Res; 2009 Nov;467(11):2825-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The remaining patient used narcotic medication and a cane or crutch only occasionally.
  • LEVEL OF EVIDENCE: Level IV, case series.
  • [MeSH-major] Arthroplasty, Replacement, Hip / methods. Bone Neoplasms / surgery. Hemipelvectomy / methods. Pelvic Bones / surgery. Walking
  • [MeSH-minor] Activities of Daily Living. Adolescent. Adult. Chondrosarcoma / mortality. Chondrosarcoma / pathology. Chondrosarcoma / surgery. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Osteosarcoma / mortality. Osteosarcoma / pathology. Osteosarcoma / surgery. Pain Measurement. Quality of Life. Reconstructive Surgical Procedures / methods. Retrospective Studies. Risk Assessment. Sarcoma, Ewing / mortality. Sarcoma, Ewing / pathology. Sarcoma, Ewing / surgery. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Orthop Trauma Surg. 2000;120(3-4):188-94 [10738881.001]
  • [Cites] Phys Ther. 2008 Aug;88(8):916-27 [18535089.001]
  • [Cites] Surg Oncol. 2000 Aug;9(2):83-90 [11094328.001]
  • [Cites] Int Orthop. 2001;24(6):311-5 [11294419.001]
  • [Cites] Clin Orthop Relat Res. 2001 Sep;(390):190-205 [11550866.001]
  • [Cites] Can J Surg. 2004 Apr;47(2):99-103 [15132462.001]
  • [Cites] J Bone Joint Surg Am. 1978 Sep;60(6):719-30 [701307.001]
  • [Cites] J Bone Joint Surg Am. 1978 Sep;60(6):731-46 [701308.001]
  • [Cites] J Bone Joint Surg Am. 1978 Sep;60(6):747-51 [701309.001]
  • [Cites] Cancer. 1979 Mar;43(3):806-9 [284841.001]
  • [Cites] Arch Orthop Trauma Surg. 1979 Aug;94(3):219-26 [227342.001]
  • [Cites] Surgery. 1981 Nov;90(5):900-9 [7302843.001]
  • [Cites] Int Orthop. 1982;6(1):27-33 [7107095.001]
  • [Cites] Surg Gynecol Obstet. 1984 Mar;158(3):279-82 [6701742.001]
  • [Cites] J Bone Joint Surg Br. 1985 May;67(3):413-5 [3997950.001]
  • [Cites] Orthopedics. 1987 Feb;10(2):323-7 [3562351.001]
  • [Cites] Arch Surg. 1988 Sep;123(9):1121-4 [3415464.001]
  • [Cites] Am J Surg. 1989 Nov;158(5):404-8 [2817220.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Am Coll Surg. 1995 Jul;181(1):43-8 [7599770.001]
  • [Cites] Eur J Surg Oncol. 1996 Apr;22(2):158-61 [8608833.001]
  • [Cites] Arch Orthop Trauma Surg. 1997;116(1-2):27-31 [9006761.001]
  • [Cites] J Bone Joint Surg Br. 1997 Sep;79(5):773-9 [9331034.001]
  • [Cites] J Bone Joint Surg Am. 1997 Nov;79(11):1663-74 [9384426.001]
  • [Cites] Arch Orthop Trauma Surg. 1998;117(6-7):408-10 [9709866.001]
  • [Cites] Langenbecks Arch Surg. 1998 Oct;383(5):359-63 [9860232.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:30-5 [16131866.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:36-41 [16131867.001]
  • [Cites] J Orthop Surg (Hong Kong). 2005 Dec;13(3):273-9 [16365491.001]
  • [Cites] J Bone Joint Surg Am. 2006 Mar;88(3):575-82 [16510825.001]
  • [Cites] J Orthop Surg (Hong Kong). 2006 Aug;14(2):155-62 [16914780.001]
  • [Cites] J Bone Joint Surg Am. 2007 Mar;89(3):579-87 [17332107.001]
  • [Cites] J Arthroplasty. 2007 Oct;22(7):981-6 [17920469.001]
  • [Cites] Z Orthop Unfall. 2007 Nov-Dec;145(6):753-9 [18072042.001]
  • [Cites] Clin Orthop Relat Res. 2008 Feb;466(2):258-63 [18196404.001]
  • [Cites] Plast Reconstr Surg. 2008 Jun;121(6):1993-2000 [18520887.001]
  • [Cites] Eur J Surg Oncol. 2000 Jun;26(4):398-404 [10873363.001]
  • (PMID = 19384561.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2758972
  •  go-up   go-down


5. Riccio AI, Wodajo FM, Malawer M: Metastatic carcinoma of the long bones. Am Fam Physician; 2007 Nov 15;76(10):1489-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast, prostate, renal, thyroid, and lung carcinomas commonly metastasize to bone.
  • If plain-film radiography is not sufficient for diagnosis, a bone scan may detect occult lesions.
  • Destructive lesions in the proximal femur and hip area are particularly worrisome.
  • Patients who are not at risk for impending fracture can be treated with a combination of radiotherapy and adjuvant drug therapy.
  • [MeSH-major] Bone Neoplasms. Carcinoma. Femur
  • [MeSH-minor] Biopsy. Combined Modality Therapy / methods. Diagnostic Imaging. Humans. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18052014.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


6. Diefenderfer DL, Osyczka AM, Garino JP, Leboy PS: Regulation of BMP-induced transcription in cultured human bone marrow stromal cells. J Bone Joint Surg Am; 2003;85-A Suppl 3:19-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of BMP-induced transcription in cultured human bone marrow stromal cells.
  • BACKGROUND: Adherent bone marrow stromal cells are inducible osteoprogenitors, giving rise to cells expressing osteoblast markers including alkaline phosphatase, osteopontin, osteocalcin, and bone sialoprotein.
  • Glucocorticoids such as dexamethasone induce alkaline phosphatase activity in both human and rat mesenchymal stem cells, while mouse bone marrow stromal cells are refractory to dexamethasone-induced alkaline phosphatase activity.
  • In contrast, BMP induces alkaline phosphatase activity in both mouse and rat bone marrow stromal cells, while BMP effects on human bone marrow stromal cells are poorly characterized.
  • METHODS: Bone marrow samples were isolated from patients undergoing hip replacement.
  • RESULTS: Bone marrow stromal cells from twenty-four of twenty-six patients showed no significant osteogenic response to BMP-2, 4, or 7 as determined by alkaline phosphatase induction.
  • However, BMPs induced elevated levels of other genes associated with osteogenesis such as bone sialoprotein and osteopontin as well as BMP-2 and noggin.
  • If primary cultures of human bone marrow stromal cells were pretreated with dexamethasone, BMP-2 treatment of first-passage cells induced alkaline phosphatase in approximately half of the isolates, and significantly greater induction was seen in cells from males.
  • CONCLUSIONS: Most human femur bone marrow stromal cell samples appear incapable of expressing elevated alkaline phosphatase levels in response to BMPs.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Calcif Tissue Int. 2002 Jul;71(1):36-44 [12200657.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9445-9 [12082181.001]
  • [Cites] J Cell Physiol. 1990 Jun;143(3):420-30 [1694181.001]
  • [Cites] J Cell Physiol. 1991 Mar;146(3):370-8 [2022691.001]
  • [Cites] Bone. 1992;13 Suppl 1:S3-6 [1581117.001]
  • [Cites] Endocrinology. 1994 Jan;134(1):277-86 [8275945.001]
  • [Cites] Dev Biol. 1994 Jan;161(1):218-28 [8293874.001]
  • [Cites] Arch Oral Biol. 1994 Nov;39(11):941-7 [7695507.001]
  • [Cites] Calcif Tissue Int. 1996 Oct;59(4):265-70 [8781050.001]
  • [Cites] J Bone Miner Res. 1996 Mar;11(3):312-24 [8852942.001]
  • [Cites] J Cell Biochem. 1997 Feb;64(2):295-312 [9027589.001]
  • [Cites] Oncogene. 2002 Oct 17;21(47):7156-63 [12370805.001]
  • [Cites] Clin Orthop Relat Res. 2002 Feb;(395):33-43 [11937864.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5330-8 [11714695.001]
  • [Cites] Bone. 2002 Jan;30(1):26-31 [11792561.001]
  • [Cites] J Bone Miner Res. 2001 Dec;16(12):2192-204 [11760832.001]
  • [Cites] J Cell Biochem. 2001;82(4):583-90 [11500936.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):31171-8 [11395499.001]
  • [Cites] Blood Cells Mol Dis. 2001 May-Jun;27(3):677-90 [11482883.001]
  • [Cites] Trends Biotechnol. 2001 Jul;19(7):255-65 [11412949.001]
  • [Cites] J Bone Miner Res. 2001 Jun;16(6):1120-9 [11393789.001]
  • [Cites] J Bone Miner Res. 1997 Oct;12(10):1606-14 [9333121.001]
  • [Cites] J Bone Joint Surg Am. 2001;83-A Suppl 1(Pt 2):S161-3 [11314797.001]
  • [Cites] J Bone Joint Surg Am. 2001;83-A Suppl 1(Pt 2):S161 [11314796.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10119-25 [11139569.001]
  • [Cites] J Cell Biochem. 2001;81(1):23-38 [11180395.001]
  • [Cites] Exp Cell Res. 2001 Jan 1;262(1):69-74 [11120606.001]
  • [Cites] J Bone Miner Res. 2000 Oct;15(10):1879-88 [11028439.001]
  • [Cites] J Bone Joint Surg Am. 2001;83-A Suppl 1(Pt 2):S163-4 [11314798.001]
  • [Cites] Bone. 1997 Jul;21(1):7-15 [9213002.001]
  • [Cites] Transplantation. 1997 Apr 27;63(8):1059-69 [9133465.001]
  • [Cites] Endocrinology. 1997 May;138(5):2117-27 [9112412.001]
  • [Cites] J Bone Miner Res. 1999 Sep;14(9):1522-35 [10469280.001]
  • [Cites] J Biol Chem. 1999 May 7;274(19):13711-7 [10224145.001]
  • [Cites] J Clin Invest. 1998 Dec 15;102(12):2106-14 [9854046.001]
  • [Cites] Bone. 1998 Aug;23(2):119-25 [9701470.001]
  • [Cites] J Cell Biochem. 1998 Mar 15;68(4):411-26 [9493905.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 29;241(3):787-93 [9434787.001]
  • [Cites] J Cell Biochem. 1997 Dec 1;67(3):386-96 [9361193.001]
  • [Cites] J Bone Miner Res. 1999 Dec;14(12):2015-26 [10620060.001]
  • [Cites] Eur J Endocrinol. 2000 Jan;142(1):9-21 [10633215.001]
  • [Cites] J Cell Biochem. 1999 Jun 15;73(4):437-44 [10733338.001]
  • [Cites] Crit Rev Oral Biol Med. 1999;10(2):165-81 [10759420.001]
  • [Cites] J Bone Miner Res. 2000 Apr;15(4):663-73 [10780858.001]
  • [Cites] Biochem Soc Trans. 1998 Feb;26(1):21-7 [10909751.001]
  • [Cites] Science. 2000 Sep 1;289(5484):1498-500 [10991738.001]
  • (PMID = 12925605.001).
  • [ISSN] 0021-9355
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE013962; United States / NIDCR NIH HHS / DE / DE13962; United States / NIDCR NIH HHS / DE / R01 DE013962-01; United States / NIDCR NIH HHS / DE / R01 DE013962-02
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BMP2 protein, human; 0 / Bmp2 protein, mouse; 0 / Bmp2 protein, rat; 0 / Bone Morphogenetic Protein 2; 0 / Bone Morphogenetic Proteins; 0 / Carrier Proteins; 0 / Neoplasm Proteins; 0 / Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / Transforming Growth Factor beta; 148294-77-3 / noggin protein; 7S5I7G3JQL / Dexamethasone; EC 3.1.3.1 / Alkaline Phosphatase
  • [Other-IDs] NLM/ NIHMS5245; NLM/ PMC1351076
  •  go-up   go-down


7. Mann BS, Johnson JR, Kelly R, Sridhara R, Williams G, Pazdur R: Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clin Cancer Res; 2005 Aug 15;11(16):5671-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To present the basis of the decision of the Food and Drug Administration to grant accelerated approval for letrozole for extended adjuvant treatment of early-stage breast cancer in postmenopausal women after completion of adjuvant tamoxifen.
  • EXPERIMENTAL DESIGN: The Food and Drug Administration reviewed the data from the MA17 trial, a single, multinational, randomized, double-blind, and placebo-controlled trial, submitted by the applicant to support the proposed new indication.
  • RESULTS: MA17 consisted of a core study and Lipid and Bone Mineral Density safety substudies.
  • Hot flushes, arthralgia/arthritis, myalgia, and new diagnosis of osteoporosis were more common on letrozole.
  • A statistically significant mean decrease in bone mineral density in the hip occurred at 24 months on letrozole.
  • [MeSH-major] Breast Neoplasms / drug therapy. Drug Approval. Nitriles / therapeutic use. Postmenopause / drug effects. Tamoxifen / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Aromatase Inhibitors / adverse effects. Aromatase Inhibitors / therapeutic use. Bone Density / drug effects. Chemotherapy, Adjuvant. Disease-Free Survival. Dizziness / chemically induced. Double-Blind Method. Female. Follow-Up Studies. Headache / chemically induced. Humans. Middle Aged. Multicenter Studies as Topic. Neoplasm Staging. Randomized Controlled Trials as Topic. Skin Diseases / chemically induced. Time Factors. Treatment Outcome. United States. United States Food and Drug Administration

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. LETROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115902.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 094ZI81Y45 / Tamoxifen; 7LKK855W8I / letrozole
  •  go-up   go-down


8. Jiménez Heffernan A, Contreras Puertas PI, Rebollo Aguirre AC: [99mTc-labelled antigranulocyte anibody fragment Fab scintigraphy (sulesomab, leukoscan) and three-phase bone scintigraphy in the study of painful hip and knee prosthesis]. Rev Esp Med Nucl; 2002 Jul;21(4):286-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [99mTc-labelled antigranulocyte anibody fragment Fab scintigraphy (sulesomab, leukoscan) and three-phase bone scintigraphy in the study of painful hip and knee prosthesis].
  • [Transliterated title] Gammagrafía con fragmentos Fab' antigranulocitos-99mTc (sulesomab, leukoscan) y ósea en tres fases en el estudio de las prótesis de cadera y rodilla dolorosas.
  • We aim to assess the diagnostic utility of the combination of a three phase bone scintigraphy (3FBS) and scintigraphy with Fab'antigranulocyte fragments-99mTc (Sulesomab, Leukoscan) in patients with painful joint replacements.
  • We studied 29 patients (22 women and 7 men with mean age 64 years) with knee (15) and hip (14) prosthesis.
  • Sulesomab images were obtained at 1 and 4 hours following injection of 740 MBq, with 300,000 cts per view (knee) and 500,000 cts per view (hip).
  • Both scintigraphic studies were interpreted visually by two nuclear medicine physicians with a 0, 1, 2, 3 score corresponding to normal or mild, moderate or intense hyperactivity respectively.
  • Interpretation criteria for bone infection was Sulesomab uptake grade 2 or 3 in a moderate or large sized area, with congruent hyperactivity on the bone scan.
  • Diagnostic confirmation procedures were surgery and culture (9) and follow-up (20).
  • [MeSH-major] Antibodies, Monoclonal. Arthritis, Infectious / radionuclide imaging. Arthroplasty, Replacement, Hip. Arthroplasty, Replacement, Knee. Cell Adhesion Molecules. Granulocytes / immunology. Hip Joint / radionuclide imaging. Immunoglobulin Fab Fragments. Knee Joint / radionuclide imaging. Pain, Postoperative / radionuclide imaging. Radiopharmaceuticals. Surgical Wound Infection / radionuclide imaging. Synovitis / radionuclide imaging. Technetium. Technetium Tc 99m Medronate
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antibody Specificity. Antigens, Neoplasm / immunology. Biomarkers. Bone Remodeling. Humans. Membrane Glycoproteins / immunology. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • MedlinePlus Health Information. consumer health - Infectious Arthritis.
  • MedlinePlus Health Information. consumer health - Knee Replacement.
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12206742.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / Cell Adhesion Molecules; 0 / Immunoglobulin Fab Fragments; 0 / Membrane Glycoproteins; 0 / Radiopharmaceuticals; 709B6VM65P / Sulesomab; 7440-26-8 / Technetium; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


9. Idan A, Griffiths KA, Harwood DT, Seibel MJ, Turner L, Conway AJ, Handelsman DJ: Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. Ann Intern Med; 2010 Nov 16;153(10):621-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MEASUREMENTS: Prostate volume was measured by ultrasonography; bone mineral density (BMD) and body composition were measured by dual-energy x-ray absorptiometry; and blood samples and questionnaires were collected every 6 months, with data analyzed by mixed-model analysis for repeated measures.
  • Dihydrotestosterone treatment decreased spinal BMD (1.4% [CI, 0.6% to 2.3%]; P < 0.001) at 24 months but not hip BMD (P > 0.2) and increased serum aminoterminal propeptide of type I procollagen in the second year of the study compared with placebo.
  • CONCLUSION: Dihydrotestosterone treatment for 24 months has no beneficial or adverse effect on prostate growth but causes a decrease in spinal but not hip BMD.
  • [MeSH-major] Androgens / administration & dosage. Dihydrotestosterone / administration & dosage. Prostate / drug effects. Prostate / growth & development
  • [MeSH-minor] Administration, Cutaneous. Antigens, Neoplasm / blood. Body Composition / drug effects. Bone Density / drug effects. Collagen Type I / blood. Double-Blind Method. Estradiol / blood. Fetal Proteins. Gels. Humans. Luteinizing Hormone / blood. Male. Middle Aged. Peptide Fragments. Procollagen. Prostate-Specific Antigen / blood. Prostatic Hyperplasia / prevention & control. Testosterone / blood

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Intern Med. 2010 Nov 16;153(10):678-9 [21079226.001]
  • [CommentIn] Praxis (Bern 1994). 2011 Mar 2;100(5):319-20 [21365566.001]
  • [SummaryForPatientsIn] Ann Intern Med. 2010 Nov 16;153(10):I38 [21079202.001]
  • (PMID = 21079217.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antigens, Neoplasm; 0 / Collagen Type I; 0 / Fetal Proteins; 0 / Gels; 0 / Peptide Fragments; 0 / Procollagen; 0 / procollagen Type I N-terminal peptide; 08J2K08A3Y / Dihydrotestosterone; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


10. Damron TA, Sim FH: Surgical treatment for metastatic disease of the pelvis and the proximal end of the femur. Instr Course Lect; 2000;49:461-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advances in the treatment of invasive cancers continue to improve the longevity of patients who have these diseases; thus, the care of patients who have bone metastases is an issue of the utmost importance to the orthopaedic surgeon.
  • The oncologist, radiotherapist, rehabilitation medicine specialist, radiologist, and pathologist each have a role to play.
  • [MeSH-major] Bone Neoplasms / secondary. Femoral Neoplasms / secondary. Pelvic Bones / surgery
  • [MeSH-minor] Arthroplasty, Replacement, Hip. Fractures, Spontaneous / pathology. Fractures, Spontaneous / surgery. Humans. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10829199.001).
  • [ISSN] 0065-6895
  • [Journal-full-title] Instructional course lectures
  • [ISO-abbreviation] Instr Course Lect
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 49
  •  go-up   go-down


11. Fu M, Shen JN, Huang G, Wang J, Fu QZ, Yang ZH: [Reconstruction of the hemipelvis with saddle prosthesis after excision of malignant tumors around the pelvis and acetabulum: a report of 12 cases]. Ai Zheng; 2007 Nov;26(11):1237-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The characteristics of the operating for this disease were analyzed in terms of preoperative preparation, operating strategy, prosthesis design, operating procedure, acetabular reconstruction, and postoperative rehabilitation.
  • According to Harris scoring criteria after total hip replacement, 3 patients scored 60-69, 5 scored 70-79, and 4 scored 80-90 in limb function.
  • For bone tumors with relatively low malignancy, this surgical treatment is an ideal option.
  • [MeSH-major] Acetabulum / surgery. Arthroplasty, Replacement, Hip / methods. Bone Neoplasms / surgery. Chondrosarcoma / surgery. Hip Prosthesis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Osteosarcoma / drug therapy. Osteosarcoma / secondary. Osteosarcoma / surgery. Pelvic Bones / surgery. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991325.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


12. Yau T, Leong CH, Chan WK, Chan JK, Liang RH, Epstein RJ: A case of mixed adult Wilms' tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO). Cancer Chemother Pharmacol; 2008 Apr;61(4):717-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A computed tomographic (CT) scan confirmed a massive renal tumour associated with extensive retroperitoneal lymph node involvement, bony metastases and a right hip fracture.
  • Histopathology revealed differentiated adult Wilms' tumour with renal angiosarcoma, whereas the pathology of the para-aortic lymph node and bone metastasis revealed angiosarcoma only.
  • This case suggests that highly angiogenic tumours such as angiosarcoma may be effectively palliated using agents usually reserved for refractory Wilms' tumour, and supports the view that adult Wilms' tumour is more sensitive to such agents.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hemangiosarcoma / drug therapy. Kidney Neoplasms / drug therapy. Wilms Tumor / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carboplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis. Neoplasm Recurrence, Local. Platelet Count. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571263.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


13. Scierski W, Polok A, Namysłowski G, Błazewicz M, Pamuła E, Stodolak E, Nozyński J, Zwirska-Korczala K, Szwarc K, Misiołek M, Czecior E, Turecka L, Lisowska G, Orecka B: [Study of selected biomaterials for reconstruction of septal nasal perforation]. Otolaryngol Pol; 2007;61(5):842-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The septal nasal perforation is an important problem for the laryngologists and plastic surgeons.
  • The reasons of septal nasal perforations are injuries, neoplasm, self-mutilation, chronic rhinitis, allergy, Wegener granuloma, sarcoidosis, tuberculosis, toxic metals (arsenic, chrome), some drugs (steroids), narcotizing agents (cocaine) and complications after endoscopic and septal nasal operations.
  • The following autogenous tissues were used in the reconstruction of septal perforation: alloderm, temporal fascia, septal and auricle cartilage, cranial periosteum, perichondrium, ethmoidal and hip bone.
  • The aim of our study was to evaluate two different biomaterials with proper mechanical and biological features for nasal cartilage replacement.
  • The pilot studies were performed on two experimental animals (rabbits).
  • The animals were operated in the general anesthesia.
  • [MeSH-minor] Animals. Polyglutamic Acid / analogs & derivatives. Polylysine / analogs & derivatives. Polytetrafluoroethylene. Rabbits. Reconstructive Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Nose Injuries and Disorders.
  • Hazardous Substances Data Bank. TEFLON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552032.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biocompatible Materials; 25104-18-1 / Polylysine; 25513-46-6 / Polyglutamic Acid; 27456-64-0 / poly(glutamic acid-lysine); 9002-84-0 / Polytetrafluoroethylene
  •  go-up   go-down


14. Bojko P, Hilger RA, Ruehm SG, Dirsch O, Seeber S, Scheulen ME: Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. Bone Marrow Transplant; 2003 Mar;31(6):487-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report three patients with relapsed ovarian cancer who developed femoral head necrosis requiring endoprosthetic hip surgery 16-35 months after high-dose chemotherapy (HDC) with treosulfan (47 and 56 g/m(2) body-surface area (BSA)) given as 3-25 h infusions and followed by autologous peripheral blood stem cell (PBSC) transplantation.
  • One woman received two courses of single agent treosulfan while the other two patients received one course of high-dose treosulfan either preceded or followed by high-dose carboplatin, etoposide and cyclophosphamide.
  • Femoral head necrosis was not observed in patients either receiving conditioning regimens without treosulfan (n=9) or when the total treosulfan dose was given over 3 consecutive days (n=3) or in patients with a diagnosis other than ovarian cancer and treated with high-dose treosulfan (n=10).
  • We conclude that women with relapsed ovarian cancer receiving HDC with excessive single-dose treosulfan might be at an increased risk of developing bone necrosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Alkylating / adverse effects. Busulfan / adverse effects. Busulfan / analogs & derivatives. Femur Head Necrosis / chemically induced. Hematopoietic Stem Cell Transplantation. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TREOSULFAN .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12665845.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; CO61ER3EPI / treosulfan; G1LN9045DK / Busulfan
  •  go-up   go-down


15. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA: Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer; 2009 May;9(2):77-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
  • BACKGROUND: Postmenopausal women with breast cancer receiving adjuvant aromatase inhibitors (AIs) are at risk for accelerated bone loss and subsequent fractures.
  • The ongoing Zometa-Femara Adjuvant Synergy Trial (Z-FAST) is evaluating the efficacy and safety of zoledronic acid in preventing such bone loss.
  • Delayed-start ZA was administered if the lumbar spine (LS) or total hip (TH) T score fell below -2.0 or a nontraumatic fracture occurred.
  • The primary endpoint was to compare the change from baseline in LS bone mineral density (BMD) between groups at month 12; secondary endpoints, measured at other predetermined timepoints, included comparing changes in TH BMD, LS BMD, and markers of bone turnover, fracture incidence, and time to disease recurrence.
  • Pyrexia (27 [9%] vs. 6 [2%]; P = .0002) and bone pain (39 [13%] vs. 20 [6.7%]; P = .01) were more common in up-front patients; cough (13 [4.3%] vs. 27 [9%]; P = .03) was more common in delayed patients.
  • CONCLUSION: Up-front ZA more effectively prevents AI-associated bone loss in postmenopausal women with early breast cancer than delaying therapy until substantial bone loss or fracture occurs.
  • [MeSH-major] Aromatase Inhibitors / adverse effects. Bone Density Conservation Agents / therapeutic use. Breast Neoplasms / drug therapy. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Nitriles / adverse effects. Osteoporosis, Postmenopausal / drug therapy. Triazoles / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Density / drug effects. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LETROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433387.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 0 / Nitriles; 0 / Triazoles; 6XC1PAD3KF / zoledronic acid; 7LKK855W8I / letrozole
  •  go-up   go-down






Advertisement